"Descovy, which utilizes tenofovir alafenamide (TAF), offers an alternative PrEP option with a generally improved safety profile. Studies have shown that TAF has less impact on kidney and bone health compared to TDF. This makes Descovy a favorable choice for individuals with pre-existing kidney or bone concerns. However, Descovy is a newer medication, and while its safety profile is advantageous, it is not approved for excessive vigana eptive vaginal sex, and it typically costs more than Truvada,

Truvada, containing tenofovir disoproxil fumarate (TDF), has been a widely used medication for HIV pre-exposure prophylaxis (PrEP). It benefits from extensive clinical data due to its longer availability, and generic versions are available, which can significantly reduce costs. However, TDF has been associated with potential side effects, particularly affecting kidney and bone health, which necessitates careful monitoring.